Author

Kai Yang

Shenzhen Bay Laboratory

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Neuroscience· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Alexander SpektoriD· 1 shared Andrew T. Bockus· 1 shared Aniruddha Sarkar· 1 shared Aston Jiaxi Wu· 1 shared Benedikt Kessler· 1 shared Bernard Levin· 1 shared Bishma Tuladhar· 1 shared Breena Fraga-Walton· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander SpektorORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Senescent astrocytic deposits drive cognitive decline by disrupting tripartite synapse in the aging brain

Er‐Jin Wang, Ming Chen, Yi‐Ting Wang, Shijia Wang, Zi-Han Song, Kai Yang, Jin-Tao Li, Xu‐Xu Zhuang, Wei Wang, Ming-Yue Wu, Li-Ming Xie, Zhengyu Ren, Chunping Liu, Lei Wang, Yong‐Gang Yao, , Jiahong Lu

This study identifies Senescent Astrocytic Deposits (SAD) as a mechanism linking astrocyte senescence to synaptic dysfunction and cognitive decline in aging brains.

bioRxiv · Oct 31, 2025 · PreprintNeuroscience

Au18(L-NIBC)14 targets ASC oligomerization for autoimmune disease treatment

Kai Yang, Xinyue Zhao, Zhupeng Xiao, Cheng Zeng, Lei Shen, Taolei Sun

This study identifies Au18(L-NIBC)14 as a gold nanocluster that targets ASC oligomerization, reducing inflammasome activation and improving symptoms in autoimmune disease models.

bioRxiv · Mar 25, 2025 · PreprintPharmacology & Toxicology

Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity

Shilpa Singh, Catherine E. Gleason, Min Fang, Yasmin N. Laimon, Vishal Khivansara, Shanhai Xie, Yavuz T. Durmaz, Aniruddha Sarkar, Kenneth Ngo, Varunika Savla, Yixiang Li, Muhannad Abu-Remaileh, Xinyue Li, Bishma Tuladhar, Ranya Odeh, , Matthew G. Oser

This paper develops cyclin A/B macrocyclic inhibitors that induce apoptosis in cancers with high E2F activity by blocking RxL-mediated interactions, showing efficacy in SCLC models.

bioRxiv · Aug 1, 2024 · PreprintCancer Biology